ES2127819T3 - Tratamiento de la degeneracion macular. - Google Patents

Tratamiento de la degeneracion macular.

Info

Publication number
ES2127819T3
ES2127819T3 ES93909617T ES93909617T ES2127819T3 ES 2127819 T3 ES2127819 T3 ES 2127819T3 ES 93909617 T ES93909617 T ES 93909617T ES 93909617 T ES93909617 T ES 93909617T ES 2127819 T3 ES2127819 T3 ES 2127819T3
Authority
ES
Spain
Prior art keywords
macular degeneration
treatment
disease
deprenyl
ameliorate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909617T
Other languages
English (en)
Inventor
Hastings Barbara A Fries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somerset Pharmaceuticals Inc
Original Assignee
Somerset Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals Inc filed Critical Somerset Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2127819T3 publication Critical patent/ES2127819T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Semiconductor Lasers (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTA UN METODO PARA EL TRATAMIENTO DE LA DEGENERACION MACULAR QUE CONSISTE EN LA ADMINISTRACION AL PACIENTE QUE SUFRE LA ENFERMEDAD DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE L-DEPRENILO O UN ACIDO FARMACEUTICAMENTE ACEPTABLE EN ADICION DE UNA SAL DEL MISMO DURANTE UN PERIODO DE TIEMPO SUFICIENTE PARA MEJORAR LA ENFERMEDAD.
ES93909617T 1992-04-23 1993-04-23 Tratamiento de la degeneracion macular. Expired - Lifetime ES2127819T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/872,839 US5242950A (en) 1992-04-23 1992-04-23 Treatment of macular degeneration

Publications (1)

Publication Number Publication Date
ES2127819T3 true ES2127819T3 (es) 1999-05-01

Family

ID=25360402

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909617T Expired - Lifetime ES2127819T3 (es) 1992-04-23 1993-04-23 Tratamiento de la degeneracion macular.

Country Status (14)

Country Link
US (1) US5242950A (es)
EP (1) EP0637238B1 (es)
JP (1) JP2669721B2 (es)
AT (1) ATE175348T1 (es)
AU (1) AU679679B2 (es)
BR (1) BR9306283A (es)
CA (1) CA2133998C (es)
DE (1) DE69322957T2 (es)
DK (1) DK0637238T3 (es)
ES (1) ES2127819T3 (es)
GR (1) GR3029670T3 (es)
HU (1) HU224917B1 (es)
NO (1) NO944018L (es)
WO (1) WO1993021894A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US5783606A (en) * 1995-02-10 1998-07-21 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
WO1996024346A1 (en) * 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
IL122484A0 (en) * 1995-06-07 1998-06-15 Noven Pharma Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5827652A (en) 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
ATE219358T1 (de) * 1995-11-06 2002-07-15 Somerset Pharmaceuticals Inc Sublinguale und bukkale verabreichung von selegilin
ES2178405T3 (es) 1998-03-16 2002-12-16 Somerset Pharmaceuticals Inc Uso de selegilina o de desmetilselegilina para tratar heridas, quemaduras y lesiones cutaneas.
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
PT1441708E (pt) * 2001-11-05 2009-06-18 Krele Pharmaceuticals Llc Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
US8088363B2 (en) * 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US9192586B2 (en) * 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20040180090A1 (en) * 2003-03-12 2004-09-16 Demarco Peter Treatment of macular degeneration
EP1622450A4 (en) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP1686973A4 (en) 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
ES2669585T3 (es) 2004-10-29 2018-05-28 The Regents Of The University Of California Micropartículas porosas de silicio para la entrega de fármaco para el ojo
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
JP2009544740A (ja) * 2006-07-28 2009-12-17 アルコン リサーチ， リミテッド 網膜外層の障害を治療するためのモノアミンオキシダーゼ阻害剤
CA2905205A1 (en) 2007-07-10 2009-01-15 The Regents Of The University Of California A drug delivery device comprising a porous sio2 film or a sio2/polymer film
AU2011212068B2 (en) 2010-02-03 2016-08-18 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
WO2017008059A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
CA2133998C (en) 2006-03-21
ATE175348T1 (de) 1999-01-15
JP2669721B2 (ja) 1997-10-29
HU224917B1 (en) 2006-04-28
GR3029670T3 (en) 1999-06-30
HUT72295A (en) 1996-04-29
DK0637238T3 (da) 1999-08-30
EP0637238A1 (en) 1995-02-08
US5242950A (en) 1993-09-07
HU9403052D0 (en) 1994-12-28
AU679679B2 (en) 1997-07-10
NO944018D0 (no) 1994-10-21
BR9306283A (pt) 1998-06-30
WO1993021894A2 (en) 1993-11-11
WO1993021894A3 (en) 1994-01-20
DE69322957D1 (de) 1999-02-18
DE69322957T2 (de) 1999-07-01
JPH07505906A (ja) 1995-06-29
EP0637238B1 (en) 1999-01-07
AU4033993A (en) 1993-11-29
CA2133998A1 (en) 1993-11-11
NO944018L (no) 1994-10-21

Similar Documents

Publication Publication Date Title
ES2127819T3 (es) Tratamiento de la degeneracion macular.
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ES2166381T3 (es) Tratamiento de enfermedades vasculares hiperproliferativas.
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DK0796103T3 (da) Anvendelse af røgelse til behandling af Alzheimer-sygdommen
MY104521A (en) Treatment of depression.
DE69206607T2 (de) Behandlung von kognitiven störungen.
DE69307702T2 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
CS22891A2 (en) Application of benzylphosphonic acid's derivatives for treatment of virusinduced diseases
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
DE69800906T2 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
RU93046326A (ru) Способ лечения медикаментозных эзофаго-гингиво-стоматитов
RU1821745C (en) Method for prognosticating effectiveness of efferent therapeutic treatment of patients suffering from immunocomplex diseases
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
DK8893D0 (da) Medicament for treatment or prevention of disease

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 637238

Country of ref document: ES